½ÃÀ庸°í¼­
»óǰÄÚµå
1631201

¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : °Ë»ç Ä«Å×°í¸®º°, À¯Çüº°, µ¿¹° À¯Çüº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Companion Animal Diagnostic Services Market Size, Share & Trends Analysis Report By Testing Category (Clinical Chemistry, Cytopathology), By Type, By Animal Type, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö 7.51%ÀÇ CAGRÀ» ±â·ÏÇϸç 2030³â±îÁö 139¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¹Ý·Áµ¿¹° Áø´Ü ±â¼úÀÇ ¹ßÀü, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ ¼­ºñ½º Á¦°ø È®´ë, ¹Ý·Áµ¿¹° º¸ÇèÀÇ º¸±Þ, ¹Ý·Áµ¿¹° ÁöÃâ Áõ°¡, ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ºÏ¹Ì ¹Ý·Áµ¿¹° °Ç°­ º¸Çè Çùȸ(NAPHIA)´Â ¹Ì±¹¿¡¼­ ¾à 388¸¸ ¸¶¸®ÀÇ °³°¡ º¸Çè¿¡ °¡ÀԵǾî ÀÖÀ¸¸ç, ¾à 96¸¸ ¸¶¸®ÀÇ °í¾çÀ̰¡ º¸Çè¿¡ °¡ÀԵǾî ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ´Â 2022³â±îÁö º¸Çè¿¡ °¡ÀÔÇÏ´Â ¹Ý·Áµ¿¹°ÀÇ ÃÑ ¼ö°¡ ¾à 22% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º¸Çè¿¡ °¡ÀÔÇÏ´Â º¸È£ÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü ¼­ºñ½º¸¦ Æ÷ÇÔÇÑ ¼öÀÇÇÐ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â ÇâÈÄ ¸î ³â µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ¹Ý·Áµ¿¹° ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâ°ú ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¸ðµÎ ¹ÌÃÆ½À´Ï´Ù. ¿©±â¿¡´Â ¼öÀÇÇп¡ ´ëÇÑ Á¢±Ù¼º Á¦ÇÑ, ¿î¿µ»óÀÇ ¾î·Á¿ò, ¹Ý·Áµ¿¹° °Ç°­¿¡ ´ëÇÑ ÀνÄ, Àμö°øÅëÀü¿°º´¿¡ ´ëÇÑ ¿ì·Á, °ø±Þ¸Á º´¸ñÇö»ó µîÀÌ Æ÷ÇԵ˴ϴÙ. ±×·¯³ª 2022³â¿¡´Â ÅõÀÔ ºñ¿ë »ó½Â µî °Å½Ã°æÁ¦Àû À̽´·Î ÀÎÇØ ½ÃÀå ¼ºÀå·üÀÌ µÐÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Neogen CorporationÀº ±¹³» ¹Ý·Áµ¿¹° À¯Àüü ¼­ºñ½ºÀÇ ¸ÅÃâ °¨¼Ò¸¦ º¸°íÇߴµ¥, ÀÌ´Â 2021³â È£Á¶¼¼¸¦ º¸¿´´ø ¸ÅÃâ ¼ºÀå°ú ºñ±³Çϱ⠾î·Á¿î ¼öÁØÀÔ´Ï´Ù. ÇÑÆí, IDEXX´Â 2022³â ¼­ºñ½º ºñ¿ë(½Ã¼³ºñ, ÀΰǺñ, Á¦Ç°ºñ Æ÷ÇÔ) »ó½Â°ú ¿îÀÓ ¹× ¹°·ùºñ »ó½ÂÀ¸·Î ÀÎÇØ ÃѸÅÃâ¾×¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ´Ù°í º¸°íÇß½À´Ï´Ù. ±×·¯³ª »ç¶÷µéÀÌ Àڽſ¡ ´ëÇØ ±â´ëÇÏ´Â Áø´Ü ¹× °Ç°­ °ü¸® ±âÁØÀÌ ¹Ý·Áµ¿¹°¿¡°Ôµµ °è¼Ó Àû¿ëµÇ°í Àֱ⠶§¹®¿¡ ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È °í±Þ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹Ý·Áµ¿¹° º¸ÇèÀÇ º¸±ÞÀº ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎÀÔ´Ï´Ù. Áø´Ü ¼­ºñ½º, ƯÈ÷ MRI ½ºÄµÀ̳ª À¯ÀüÀÚ °Ë»ç¿Í °°Àº °íµµÀÇ ½Ã¼úÀÇ °æ¿ì ºñ¿ëÀÌ ¸¹ÀÌ µé ¼ö ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸ÇèÀº º¸È£ÀÚÀÇ °æÁ¦Àû ºÎ´ãÀ» ÁÙ¿©ÁÖ°í, ¼öÀÇ»çÀÇ ±ÇÀ¯°¡ ÀÖÀ» ¶§ ÀÌ·¯ÇÑ ¼­ºñ½º¸¦ ¼±ÅÃÇÏ´Â °ÍÀÌ ´õ Çö½ÇÀûÀÎ ¼±ÅÃÀÌ µË´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹° º¸ÇèÀº ÀÓ»ó °Ë»ç, ¿µ»ó Áø´Ü, ±âŸ ÀÇ·á½Ã¼úÀ» Æ÷ÇÔÇÑ Áø´Ü ¼­ºñ½º ºñ¿ëÀÇ ÀϺΠ¶Ç´Â Àü¾×À» º¸ÀåÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. º¸Çè¿¡ °¡ÀÔÇÑ º¸È£ÀÚ´Â ¹Ý·Áµ¿¹°À» Á¤±âÀûÀ¸·Î ¼öÀǻ翡°Ô µ¥·Á°¥ °¡´É¼ºÀÌ ³ôÀ¸¸ç, Áø´ÜÀ» ÅëÇØ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÌ·¯ÇÑ Àû±ØÀûÀÎ Á¢±ÙÀº ¹Ý·Áµ¿¹°ÀÇ °Ç°­ »óŸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ãʱ⿡ ¹®Á¦¸¦ ÇØ°áÇÔÀ¸·Î½á Àüü Ä¡·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • »ç¶÷µéÀÌ ½º½º·Î¿¡°Ô ±â´ëÇÏ´Â Áø´Ü ¹× °Ç°­ °ü¸®ÀÇ ±âÁØÀº ¹Ý·Áµ¿¹°¿¡°Ôµµ Àû¿ëµÇ¾î °í±Þ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
  • °Ë»ç Ä«Å×°í¸®º°·Î´Â ÀÓ»óÈ­ÇÐ ºÐ¾ß°¡ 2024³â 23.67% ÀÌ»óÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ¹Ý¸é, ¼¼Æ÷º´¸®ÇÐ ºÎ¹®Àº ÇâÈÄ ¸î ³â µ¿¾È 9% ÀÌ»óÀÇ ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
  • À¯Çüº°·Î´Â ÇöÀåÁø´Ü(POC) ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ½ÇÇè½Ç ±â¹Ý ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È 7.85% ÀÌ»óÀÇ °¡Àå ºü¸¥ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • 2024³â µ¿¹° À¯Çüº° ½ÃÀå¿¡¼­´Â °³°¡ ¾à 54.69%·Î °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ±âŸ ¹Ý·Áµ¿¹° ¼¼ºÐÈ­´Â °¡±î¿î Àå·¡¿¡ 9.86% ÀÌ»óÀÇ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
  • ¹Ý·Áµ¿¹°ÀÇ ¼ö¸íÀÌ ±æ¾îÁü¿¡ µû¶ó ³ëÈ­ °ü·Ã Áúȯ°ú ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹° º¸Çè °¡ÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¸Çè Àû¿ëÀ¸·Î ºñ¿ëÀ» »ó¼âÇÒ ¼ö Àֱ⠶§¹®¿¡ ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀº ¹Ý·Áµ¿¹°ÀÇ Á¾ÇÕÀûÀÎ Áø´Ü °Ë»ç¸¦ ¹ÞÀ¸·Á´Â °æÇâÀÌ ÀÖ½À´Ï´Ù.
  • 2024³â Áö¿ªº° ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì°¡ 38.25% ÀÌ»óÀ¸·Î °¡Àå ³ô¾Ò½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È 9% ÀÌ»óÀÇ °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • COVID-19 ÆÒµ¥¹Í ¹× ±âŸ Àμö°øÅëÀü¿°º´ÀÇ ¹ß»ýÀ¸·Î µ¿¹°°ú »ç¶÷ »çÀÌ¿¡ Àü¿°µÉ ¼ö ÀÖ´Â Áúº´À» ¸ð´ÏÅ͸µÇϰí Áø´ÜÇÏ´Â °ÍÀÌ Áß¿äÇØÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ½ÃÀå °úÁ¦ ºÐ¼®
  • ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
  • 2024³âÀÇ ÁÖ¿ä Á¾°ú ±¹°¡º° ¹Ý·Áµ¿¹° ÃßÁ¤ °³Ã¼¼ö
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : °Ë»ç Ä«Å×°í¸®º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : °Ë»ç Ä«Å×°í¸®º° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À²(2024³â¡¤2030³â)
  • ÀÓ»óÈ­ÇÐ
  • ¹Ì»ý¹°ÇÐ
  • ±â»ýÃæÇÐ
  • Á¶Á÷º´¸®ÇÐ
  • ¼¼Æ÷º´¸®ÇÐ
  • Ç÷¾×ÇÐ
  • ¸é¿ªÇаú Ç÷ûÇÐ
  • À̹Ì¡
  • ºÐÀÚÁø´Ü
  • ±âŸ Ä«Å×°í¸®

Á¦5Àå ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : À¯Çüº° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À²(2024³â¡¤2030³â)
  • POC(Point of Care)
    • ÀÓ»óÈ­ÇÐ
    • ¹Ì»ý¹°ÇÐ
    • ±â»ýÃæÇÐ
    • Á¶Á÷º´¸®ÇÐ
    • ¼¼Æ÷º´¸®ÇÐ
    • Ç÷¾×ÇÐ
    • ¸é¿ªÇаú Ç÷ûÇÐ
    • À̹Ì¡
    • ºÐÀÚÁø´Ü
    • ±âŸ Ä«Å×°í¸®
  • ½ÇÇè½Ç ±â¹Ý
    • ÀÓ»óÈ­ÇÐ
    • ¹Ì»ý¹°ÇÐ
    • ±â»ýÃæÇÐ
    • Á¶Á÷º´¸®ÇÐ
    • ¼¼Æ÷º´¸®ÇÐ
    • Ç÷¾×ÇÐ
    • ¸é¿ªÇаú Ç÷ûÇÐ
    • À̹Ì¡
    • ºÐÀÚÁø´Ü
    • ±âŸ Ä«Å×°í¸®

Á¦6Àå ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : µ¿¹° À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : µ¿¹° À¯Çüº° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À²(2024³â¡¤2030³â)
  • °³
  • °í¾çÀÌ
  • ¸»
  • ±âŸ

Á¦7Àå ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª Àü¸Á
  • ¹Ý·Áµ¿¹° Áø´Ü ¼­ºñ½º ½ÃÀå : Áö¿ªº° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À²(2024³â¡¤2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ³×´ú¶õµå
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ

Á¦8Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®/heap ¸Ê ºÐ¼®
  • ±â¾÷ ½ÃÀå Á¡À¯À² ÃßÁ¤ ºÐ¼®(2024³â)
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´
    • ÆÄÆ®³Ê½Ê°ú Çù¾÷
    • ±âŸ
  • ±â¾÷ °³¿ä
    • Zoetis Services LLC
    • IDEXX Laboratories, Inc.
    • Mars Inc.
    • The Animal Medical Center
    • Embark Veterinary, Inc.
    • SYNLAB
    • NationWide Laboratories
    • IVC Evidensia
    • CVS Group Plc
    • Greencross Vets
ksm 25.02.06

Companion Animal Diagnostic Services Market Growth & Trends:

The global companion animal diagnostic services market size is expected to reach USD 13.95 billion by 2030, registering a CAGR of 7.51% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by increasing advancements in pet diagnostics, expansion of service offerings by key market players, pet insurance penetration, rising pet expenditure, and growing pet health concerns. The North American Pet Health Insurance Association (NAPHIA) for instance, reported that about 3.88 million dogs in the U.S. are insured, while about 0.96 million cats have insurance policies. This represented about 22% growth in total insured pets over 2022. As more pet owners opt for insurance coverage, the demand for veterinary services, including diagnostic services is anticipated to increase in the coming years.

The COVID-19 pandemic had both positive and negative impacts on the market. This included limited access to veterinary care, operational challenges, awareness about pet health, concerns over zoonoses, and supply chain bottlenecks. In 2022, however, the market experienced a dampened growth rate owing to the macroeconomic challenges brought on by high input costs and other factors. For example, Neogen Corporation reported a decrease in domestic pet genomics services revenue owing to a difficult comparison from strong 2021 sales growth. While IDEXX reported a notable impact on its gross profit in 2022 owing to higher service costs (including facility, labor, and product costs) and high freight and distribution costs. However, as diagnostic and healthcare standards that people expect for themselves continue to extend to their pets, it is estimated to drive the demand for sophisticated diagnostic services over the forecast period.

Increasing adoption of pet insurance is a key market driver. Diagnostic services can sometimes be expensive, particularly for advanced procedures like MRI scans or genetic testing. Pet insurance mitigates the financial burden on pet owners, making it more feasible for them to opt for these services when recommended by veterinarians. Also, pet insurance policies often cover a portion of or the entire cost of diagnostic services, including laboratory tests, imaging, and other medical procedures. Pet owners who have insurance are more likely to take their pets to the veterinarian regularly, increasing the likelihood of early disease detection through diagnostics. This proactive approach not only improves the pet's health outcomes but also reduces the overall cost of treatment by addressing issues in their early stages.

Companion Animal Diagnostic Services Market Report Highlights:

  • The diagnostic and healthcare standards that people expect for themselves are extending to their pets, driving demand for sophisticated diagnostic services
  • By Testing Category, the Clinical Chemistry segment dominated the market with a share of over 23.67% in 2024. The Cytopathology segment on the other hand, is estimated to witness the highest growth rate of more than 9% in the coming years
  • In terms of Type, the Point-of-Care (POC) segment dominated the market in 2024. The Laboratory-based segment is projected to grow at the fastest rate of over 7.85% during the forecast period
  • Dogs accounted for the highest share of about 54.69% of the market by animal type in 2024. Other companion animals segment is estimated to witness the highest CAGR of over 9.86% in the near future
  • As pets live longer, the prevalence of age-related conditions and chronic diseases increases, leading to a higher demand for diagnostic services. Furthermore, the rise in pet insurance adoption encourages pet owners to seek comprehensive diagnostic testing for their pets, as insurance coverage can offset costs
  • In 2024, North America held the highest share of over 38.25% of the market by region. The Asia Pacific region is expected to grow at the fastest rate of over 9% during the forecast period
  • The COVID-19 pandemic and other zoonotic disease outbreaks have underscored the importance of monitoring and diagnosing diseases that can be transmitted between animals and humans thus fueling the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Companion Animal Diagnostic Services Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing humanization of pets
      • 3.2.1.2. Increasing medicalization rate
      • 3.2.1.3. Increasing uptake of point-of-care diagnostics
      • 3.2.1.4. Increasing technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of awareness
      • 3.2.2.2. Limited access to quality veterinary care
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Companion Animal Diagnostic Services Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
  • 3.4. Estimated Companion Animal Population, by key species & key countries, 2024
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Companion Animal Diagnostic Services Market: Testing Category Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Companion Animal Diagnostic Services Market: Testing Category Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Clinical Chemistry
    • 4.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Microbiology
    • 4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Parasitology
    • 4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Histopathology
    • 4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Cytopathology
    • 4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Hematology
    • 4.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Immunology & Serology
    • 4.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Imaging
    • 4.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.11. Molecular Diagnostics
    • 4.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.12. Other Categories
    • 4.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Companion Animal Diagnostic Services Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Companion Animal Diagnostic Services Market: Type Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Point-of-Care (POC)
    • 5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Clinical Chemistry
      • 5.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Microbiology
      • 5.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Parasitology
      • 5.3.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Histopathology
      • 5.3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Cytopathology
      • 5.3.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Hematology
      • 5.3.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Immunology & Serology
      • 5.3.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Imaging
      • 5.3.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.10. Molecular Diagnostics
      • 5.3.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.11. Other Categories
      • 5.3.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Laboratory-based
    • 5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Clinical Chemistry
      • 5.4.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Microbiology
      • 5.4.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Parasitology
      • 5.4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Histopathology
      • 5.4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Cytopathology
      • 5.4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.7. Hematology
      • 5.4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.8. Immunology & Serology
      • 5.4.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.9. Imaging
      • 5.4.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.10. Molecular Diagnostics
      • 5.4.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.11. Other Categories
      • 5.4.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Companion Animal Diagnostic Services Market: Animal Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Companion Animal Diagnostic Services Market: Animal Type Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Dogs
    • 6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Cats
    • 6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Horses
    • 6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Companion Animal Diagnostic Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Companion Animal Diagnostic Services Market: Regional Movement Analysis & Market Share, 2024 & 2030
  • 7.3. North America
    • 7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Netherlands
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.9. Sweden
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Mexico
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Middle East & Africa
    • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Estimated Company Market Share Analysis, 2024
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Others
  • 8.5. Company Profiles
    • 8.5.1. Zoetis Services LLC
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Testing Category Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. IDEXX Laboratories, Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Testing Category Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Mars Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Testing Category Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. The Animal Medical Center
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Testing Category Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Embark Veterinary, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Testing Category Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. SYNLAB
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Testing Category Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. NationWide Laboratories
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Testing Category Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. IVC Evidensia
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Testing Category Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. CVS Group Plc
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Testing Category Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Greencross Vets
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Testing Category Benchmarking
      • 8.5.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦